OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
Sitthichai Kanokudom, Suvichada Assawakosri, Nungruthai Suntronwong, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 86-86
Open Access | Times Cited: 85
Sitthichai Kanokudom, Suvichada Assawakosri, Nungruthai Suntronwong, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 86-86
Open Access | Times Cited: 85
Showing 1-25 of 85 citing articles:
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
Sue Ann Costa Clemens, Lily Yin Weckx, Ralf Clemens, et al.
The Lancet (2022) Vol. 399, Iss. 10324, pp. 521-529
Open Access | Times Cited: 414
Sue Ann Costa Clemens, Lily Yin Weckx, Ralf Clemens, et al.
The Lancet (2022) Vol. 399, Iss. 10324, pp. 521-529
Open Access | Times Cited: 414
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
Suvichada Assawakosri, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 8, pp. 1372-1381
Open Access | Times Cited: 57
Suvichada Assawakosri, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 8, pp. 1372-1381
Open Access | Times Cited: 57
Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world
Vivek P. Chavda, Qian Yao, Lalitkumar K. Vora, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Vivek P. Chavda, Qian Yao, Lalitkumar K. Vora, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
Rontgene Solante, Carlos Álvarez, Erlina Burhan, et al.
Expert Review of Vaccines (2022) Vol. 22, Iss. 1, pp. 1-16
Open Access | Times Cited: 43
Rontgene Solante, Carlos Álvarez, Erlina Burhan, et al.
Expert Review of Vaccines (2022) Vol. 22, Iss. 1, pp. 1-16
Open Access | Times Cited: 43
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis
Masoud Etemadifar, Hosein Nouri, Maristella Pitzalis, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 93, Iss. 9, pp. 986-994
Open Access | Times Cited: 36
Masoud Etemadifar, Hosein Nouri, Maristella Pitzalis, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 93, Iss. 9, pp. 986-994
Open Access | Times Cited: 36
Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England
Freja Kirsebom, Nick Andrews, Ruchira Sachdeva, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 32
Freja Kirsebom, Nick Andrews, Ruchira Sachdeva, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 32
Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
Haoyue Cheng, Zhicheng Peng, Shuting Si, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 798-798
Open Access | Times Cited: 31
Haoyue Cheng, Zhicheng Peng, Shuting Si, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 798-798
Open Access | Times Cited: 31
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
Yuemiao Zhang, Xupu Ma, Guanghong Yan, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101680-101680
Open Access | Times Cited: 29
Yuemiao Zhang, Xupu Ma, Guanghong Yan, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101680-101680
Open Access | Times Cited: 29
Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia
Eddy Fadlyana, Djatnika Setiabudi, Cissy B. Kartasasmita, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 5, pp. 545-555
Open Access | Times Cited: 20
Eddy Fadlyana, Djatnika Setiabudi, Cissy B. Kartasasmita, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 5, pp. 545-555
Open Access | Times Cited: 20
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial
Jundong Wu, Jingxin Li, Jian Liu, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 9, pp. 1020-1030
Closed Access | Times Cited: 19
Jundong Wu, Jingxin Li, Jian Liu, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 9, pp. 1020-1030
Closed Access | Times Cited: 19
COVID-19 Vaccines, Effectiveness, and Immune Responses
Haneen I. Abufares, Leen Oyoun Alsoud, Mohammad A. Y. Alqudah, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15415-15415
Open Access | Times Cited: 28
Haneen I. Abufares, Leen Oyoun Alsoud, Mohammad A. Y. Alqudah, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15415-15415
Open Access | Times Cited: 28
Effect of BTN162b2 and CoronaVac boosters on humoral and cellular immunity of individuals previously fully vaccinated with CoronaVac against SARS‐CoV‐2: A longitudinal study
Zeynep Ece Kuloğlu, Rojbin El, Gülen Güney-Esken, et al.
Allergy (2022) Vol. 77, Iss. 8, pp. 2459-2467
Open Access | Times Cited: 23
Zeynep Ece Kuloğlu, Rojbin El, Gülen Güney-Esken, et al.
Allergy (2022) Vol. 77, Iss. 8, pp. 2459-2467
Open Access | Times Cited: 23
Real-World Effectiveness of Mix-and-Match Vaccine Regimens against SARS-CoV-2 Delta Variant in Thailand: A Nationwide Test-Negative Matched Case-Control Study
Rapeepong Suphanchaimat, Natthaprang Nittayasoot, Chuleeporn Jiraphongsa, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1080-1080
Open Access | Times Cited: 23
Rapeepong Suphanchaimat, Natthaprang Nittayasoot, Chuleeporn Jiraphongsa, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1080-1080
Open Access | Times Cited: 23
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
Theerada Assawasaksakul, Seelwan Sathitratanacheewin, Preeyaporn Vichaiwattana, et al.
Lupus Science & Medicine (2022) Vol. 9, Iss. 1, pp. e000726-e000726
Open Access | Times Cited: 22
Theerada Assawasaksakul, Seelwan Sathitratanacheewin, Preeyaporn Vichaiwattana, et al.
Lupus Science & Medicine (2022) Vol. 9, Iss. 1, pp. e000726-e000726
Open Access | Times Cited: 22
Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers
Watsamon Jantarabenjakul, Pimpayao Sodsai, Napaporn Chantasrisawad, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 639-639
Open Access | Times Cited: 21
Watsamon Jantarabenjakul, Pimpayao Sodsai, Napaporn Chantasrisawad, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 639-639
Open Access | Times Cited: 21
Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
Eveline Santos da Silva, Jean-Yves Servais, Michel Kohnen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14965-14965
Open Access | Times Cited: 13
Eveline Santos da Silva, Jean-Yves Servais, Michel Kohnen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14965-14965
Open Access | Times Cited: 13
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
Moe H. Kyaw, Júlia Spinardi, Ling Zhang, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 11
Moe H. Kyaw, Júlia Spinardi, Ling Zhang, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 11
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
Suvichada Assawakosri, Sitthichai Kanokudom, Jira Chansaenroj, et al.
International Journal of Infectious Diseases (2022) Vol. 122, pp. 793-801
Open Access | Times Cited: 17
Suvichada Assawakosri, Sitthichai Kanokudom, Jira Chansaenroj, et al.
International Journal of Infectious Diseases (2022) Vol. 122, pp. 793-801
Open Access | Times Cited: 17
Neutralizing and binding antibody dynamics following primary and booster COVID-19 vaccination among healthcare workers
Irmak Güzel, Gamze ÖZTÜRK, Özgür Appak, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
Irmak Güzel, Gamze ÖZTÜRK, Özgür Appak, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, et al.
International Journal of Infectious Diseases (2022) Vol. 126, pp. 64-72
Open Access | Times Cited: 15
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, et al.
International Journal of Infectious Diseases (2022) Vol. 126, pp. 64-72
Open Access | Times Cited: 15
Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)
Yi Fang, Jingxin Li, Davone Duangdany, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102372-102372
Open Access | Times Cited: 9
Yi Fang, Jingxin Li, Davone Duangdany, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102372-102372
Open Access | Times Cited: 9
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial
Saeed Erfanpoor, Seyed Reza Banihashemi, Ladan Mokhbaeralsafa, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Saeed Erfanpoor, Seyed Reza Banihashemi, Ladan Mokhbaeralsafa, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study
Mangaiarkarasi Asokan, Roshni Florina Joan, Sudhir Babji, et al.
The Lancet Regional Health - Southeast Asia (2024) Vol. 22, pp. 100361-100361
Open Access | Times Cited: 3
Mangaiarkarasi Asokan, Roshni Florina Joan, Sudhir Babji, et al.
The Lancet Regional Health - Southeast Asia (2024) Vol. 22, pp. 100361-100361
Open Access | Times Cited: 3
Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial
Suad Hannawi, Xiaohong Wu, Ralph Elvi Villalobos, et al.
Med (2024) Vol. 5, Iss. 10, pp. 1282-1292.e3
Open Access | Times Cited: 3
Suad Hannawi, Xiaohong Wu, Ralph Elvi Villalobos, et al.
Med (2024) Vol. 5, Iss. 10, pp. 1282-1292.e3
Open Access | Times Cited: 3
Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies
Mariana Barosa, John P. A. Ioannidis, Vinay Prasad
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 10
Open Access | Times Cited: 3
Mariana Barosa, John P. A. Ioannidis, Vinay Prasad
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 10
Open Access | Times Cited: 3
